Interdisciplinary Perspectives on Opioid Toxicity: Nursing, Medical, and Health Security Dimensions
Abstract
Background: Opioid toxicity represents a critical public health crisis, characterized by a sharp rise in misuse, addiction, and fatal overdoses. This complex issue stems from the pharmacological effects of opioids on the central nervous system, particularly respiratory depression, and is fueled by a combination of prescribing practices, patient vulnerabilities, and social determinants.
Aim: This review aims to synthesize interdisciplinary perspectives on opioid toxicity, focusing on the integrated roles of nursing, medical management, and health security in prevention, acute intervention, and long-term harm reduction.
Methods: The analysis is based on a comprehensive review of clinical practices, including patient assessment, diagnostic criteria, and treatment protocols. It evaluates medical management strategies like Medication-Assisted Treatment (MAT) and nursing interventions for acute toxicity and monitoring. Health security dimensions, such as prescription drug monitoring programs and secure storage, are also examined.
Results: Effective management requires a coordinated, multi-pronged approach. Key findings highlight the efficacy of naloxone for overdose reversal, the central role of MAT (e.g., buprenorphine, methadone) in treating Opioid Use Disorder (OUD), and the critical importance of nursing in continuous monitoring, patient education, and risk assessment. Health security measures are essential for preventing diversion.
Conclusion: Combating the opioid epidemic necessitates a unified strategy that bridges clinical care and public health. Interprofessional collaboration among nurses, physicians, pharmacists, and health security professionals is paramount to ensuring safe prescribing, effective overdose response, and sustainable recovery, thereby reducing morbidity and mortality.
Full text article
References
Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013 Jun 01;87(11):766-72.
Lalic S, Jokanovic N, Ilomäki J, Gisev N, Lloyd B, Lubman DI, Bell JS. Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review. Res Social Adm Pharm. 2019 Aug;15(8):925-935.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018 Jan;9(1):63-88.
Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010 Jan 19;152(2):85-92.
LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol. 2000 Dec 27;410(2-3):249-268.
Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005 Mar;57(1):1-26.
Caffrey CR, Lank PM. When good times go bad: managing 'legal high' complications in the emergency department. Open Access Emerg Med. 2018;10:9-23.
Brady JE, Giglio R, Keyes KM, DiMaggio C, Li G. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. Inj Epidemiol. 2017 Dec;4(1):24.
Huang X, Keyes KM, Li G. Increasing Prescription Opioid and Heroin Overdose Mortality in the United States, 1999-2014: An Age-Period-Cohort Analysis. Am J Public Health. 2018 Jan;108(1):131-136.
Massey J, Kilkenny M, Batdorf S, Sanders SK, Ellison D, Halpin J, Gladden RM, Bixler D, Haddy L, Gupta R. Opioid Overdose Outbreak - West Virginia, August 2016. MMWR Morb Mortal Wkly Rep. 2017 Sep 22;66(37):975-980.
Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012 Jul;15(3 Suppl):ES67-92.
Borgundvaag B, McLeod S, Khuu W, Varner C, Tadrous M, Gomes T. Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study. CMAJ Open. 2018 Mar 01;6(1):E110-E117.
Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected? J Am Med Dir Assoc. 2005 Jul-Aug;6(4):265-9.
Sporer KA. Acute heroin overdose. Ann Intern Med. 1999 Apr 06;130(7):584-90.
Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007 Jul;61(7):1181-7.
Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998 Apr;5(4):293-9.
LoVecchio F, Pizon A, Riley B, Sami A, D'Incognito C. Onset of symptoms after methadone overdose. Am J Emerg Med. 2007 Jan;25(1):57-9.
Sporer KA, Firestone J, Isaacs SM. Out-of-hospital treatment of opioid overdoses in an urban setting. Acad Emerg Med. 1996 Jul;3(7):660-7.
Owusu Obeng A, Hamadeh I, Smith M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy. 2017 Sep;37(9):1105-1121.
Ciejka M, Nguyen K, Bluth MH, Dubey E. Drug Toxicities of Common Analgesic Medications in the Emergency Department. Clin Lab Med. 2016 Dec;36(4):761-776.
Melanson SE, Baskin L, Magnani B, Kwong TC, Dizon A, Wu AH. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Arch Pathol Lab Med. 2010 May;134(5):735-9.
Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009 Aug;10(11):1727-40.
Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse. 1984;10(2):249-66.
Wong F, Edwards CJ, Jarrell DH, Patanwala AE. Comparison of lower-dose versus higher-dose intravenous naloxone on time to recurrence of opioid toxicity in the emergency department. Clin Toxicol (Phila). 2019 Jan;57(1):19-24.
Pauly JB, Vartan CM, Brooks AT. Implementation and evaluation of an opioid overdose education and naloxone distribution (OEND) program at a Veterans Affairs Medical Center. Subst Abus. 2018;39(2):206-210.
Sivilotti ML. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016 Mar;81(3):428-36.
Saloner B, McGinty EE, Beletsky L, Bluthenthal R, Beyrer C, Botticelli M, Sherman SG. A Public Health Strategy for the Opioid Crisis. Public Health Rep. 2018 Nov/Dec;133(1_suppl):24S-34S.
Wiese B, Wilson-Poe AR. Emerging Evidence for Cannabis' Role in Opioid Use Disorder. Cannabis Cannabinoid Res. 2018;3(1):179-189.
Metfessel BA, Mentel MD, Phanel A, Dimartino MA, Allen M, Ho S. Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck. Pharmacoeconomics. 2019 Mar;37(3):419-433.
Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013 Jul;125(4):115-30.
Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom. Value Health. 2018 Apr;21(4):407-415.
Yokell MA, Zaller ND, Green TC, McKenzie M, Rich JD. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose. J Opioid Manag. 2012 Jan-Feb;8(1):63-6.
Bone C, Eysenbach L, Bell K, Barry DT. Our Ethical Obligation to Treat Opioid Use Disorder in Prisons: A Patient and Physician's Perspective. J Law Med Ethics. 2018 Jun;46(2):268-271.
Lopian KM, Chebolu E, Kulak JA, Kahn LS, Blondell RD. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder. J Subst Abuse Treat. 2019 Feb;97:1-6.
Silverberg D, Menes T, Kim U. Surgery for "body packers"--a 15-year experience. World J Surg. 2006 Apr;30(4):541-6.
Olfson M, Wall M, Wang S, Crystal S, Blanco C. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug Alcohol Depend. 2018 Sep 01;190:112-119.
Matic M, de Wildt SN, Tibboel D, van Schaik RHN. Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. Clin Chem. 2017 Jul;63(7):1204-1213.
Cobaugh DJ, Gainor C, Gaston CL, Kwong TC, Magnani B, McPherson ML, Painter JT, Krenzelok EP. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. Am J Health Syst Pharm. 2014 Sep 15;71(18):1539-54.
Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008 Jul-Aug;8(4):287-313.
Chou R, Korthuis PT, McCarty D, Coffin PO, Griffin JC, Davis-O'Reilly C, Grusing S, Daya M. Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review. Ann Intern Med. 2017 Dec 19;167(12):867-875.
Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag. 2008 Jul-Aug;4(4):213-50.
King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 2011 Jul;25(5):525-52.
Authors
Copyright (c) 2025 Faten Aden Almutairi, Mona Saleh Almutairi, Nouf Saleh Almutairi, Ahlam Ahmed Abdu Masrahi, Zahra Ibrahim Bohis Tohary, Ameerah Ali Ibrahim Somali, Asrar Hassan Yahya Daghriri, Shaima Ahmed Daghriry, Eman Ali Jassim Alsafwani, Aisha abdow hadadi, Noura Jaber Al-Asmari, Kathiyh Jaman Alyami
This work is licensed under a Creative Commons Attribution 4.0 International License.